Part I Overview We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. On July 31, 2025, the United States (U.S.) Food and Drug Administration (FDA) approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the U.S. We...
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001815776-26-000011 | EDGAR | 85K words |
| 2025-03-19 | 2024-12-31 | 0001815776-25-000019 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021135 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0000950170-23-008764 | EDGAR | — |
| 2022-03-21 | 2021-12-31 | 0001564590-22-011123 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001815776-25-000071 | EDGAR | 61K words |
| 2025-07-30 | 2025-06-30 | 0001815776-25-000056 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001815776-25-000032 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001815776-24-000071 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001815776-24-000060 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001815776-24-000042 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062942 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042525 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021242 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023869 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016869 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019862 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001815776-26-000008 | EDGAR | 3K words |
| 2026-01-07 | 0001815776-26-000003 | EDGAR | — |
| 2025-12-12 | 0001815776-25-000077 | EDGAR | — |
| 2025-11-05 | 0001815776-25-000069 | EDGAR | — |
| 2025-10-08 | 0001815776-25-000064 | EDGAR | — |
| 2025-09-30 | 0001815776-25-000062 | EDGAR | — |
| 2025-07-31 | 0001815776-25-000059 | EDGAR | — |
| 2025-07-30 | 0001815776-25-000054 | EDGAR | — |
| 2025-06-10 | 0001815776-25-000036 | EDGAR | — |
| 2025-05-07 | 0001815776-25-000030 | EDGAR | — |
89 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001815776 |
| Ticker | LENZ |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.lenz-tx.com |
| Listed | 2024-03-22 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report